OBJECTIVES: To evaluate (a) the prophylactic effect of the antiherpetic drug acyclovir on oral ulcers in patients with acute myeloid leukaemia receiving remission induction chemotherapy and thus (b), indirectly, the role of herpes simplex virus in the aetiology of these ulcers. DESIGN: Randomised, double blind, placebo controlled trial. SUBJECTS:74 herpes simplex virus seropositive patients aged 18-84. Thirty seven patients received acyclovir (800 mg by mouth daily) and 37 placebo. The patients were examined daily for 28 days. MAIN OUTCOME MEASURES: Occurrence of herpes labialis, intraoral ulcers, and acute necrotising ulcerative gingivitis. RESULTS: The two populations were comparable in age, sex, type of antineoplastic treatment, and history of herpes labialis. Acute oral infections occurred in 25 of the acyclovir treated patients and 36 of the placebo treated patients (relative risk 0.69 (95% confidence interval 0.55 to 0.87)). This difference was due to a reduction in the incidence of herpes labialis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)), intraoral ulcers excluding the soft palate (one case versus 13 cases; relative risk 0.08 (0.01 to 0.56)), and acute necrotising ulcerative gingivitis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)). However, ulcers on the soft palate were diagnosed with similar frequency in the two groups. Isolation of herpes simplex virus type 1 in saliva was reduced from 15 cases in the placebo group to one case in the acyclovir group (relative risk 0.07 (0.01 to 0.48)). CONCLUSION:Intraoral ulcers excluding the soft palate are most often due to infection with herpes simplex virus, whereas ulcers on the soft palate have a non-herpetic aetiology. The findings suggest that acute necrotising ulcerative gingivitis may also be due to herpes simplex virus. Prophylaxis with acyclovir should be considered for patients with acute myeloid leukaemia during remission induction therapy.
RCT Entities:
OBJECTIVES: To evaluate (a) the prophylactic effect of the antiherpetic drug acyclovir on oral ulcers in patients with acute myeloid leukaemia receiving remission induction chemotherapy and thus (b), indirectly, the role of herpes simplex virus in the aetiology of these ulcers. DESIGN: Randomised, double blind, placebo controlled trial. SUBJECTS: 74 herpes simplex virus seropositive patients aged 18-84. Thirty seven patients received acyclovir (800 mg by mouth daily) and 37 placebo. The patients were examined daily for 28 days. MAIN OUTCOME MEASURES: Occurrence of herpes labialis, intraoral ulcers, and acute necrotising ulcerative gingivitis. RESULTS: The two populations were comparable in age, sex, type of antineoplastic treatment, and history of herpes labialis. Acute oral infections occurred in 25 of the acyclovir treated patients and 36 of the placebo treated patients (relative risk 0.69 (95% confidence interval 0.55 to 0.87)). This difference was due to a reduction in the incidence of herpes labialis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)), intraoral ulcers excluding the soft palate (one case versus 13 cases; relative risk 0.08 (0.01 to 0.56)), and acute necrotising ulcerative gingivitis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)). However, ulcers on the soft palate were diagnosed with similar frequency in the two groups. Isolation of herpes simplex virus type 1 in saliva was reduced from 15 cases in the placebo group to one case in the acyclovir group (relative risk 0.07 (0.01 to 0.48)). CONCLUSION:Intraoral ulcers excluding the soft palate are most often due to infection with herpes simplex virus, whereas ulcers on the soft palate have a non-herpetic aetiology. The findings suggest that acute necrotising ulcerative gingivitis may also be due to herpes simplex virus. Prophylaxis with acyclovir should be considered for patients with acute myeloid leukaemia during remission induction therapy.
Authors: B Lönnqvist; J Palmblad; P Ljungman; G Grimfors; M Järnmark; R Lerner; C Nyström-Rosander; G Oberg Journal: Support Care Cancer Date: 1993-05 Impact factor: 3.603
Authors: E Gluckman; J Lotsberg; A Devergie; X M Zhao; R Melo; M Gomez-Morales; T Nebout; M C Mazeron; Y Perol Journal: Lancet Date: 1983-09-24 Impact factor: 79.321
Authors: R Saral; R F Ambinder; W H Burns; C M Angelopulos; D E Griffin; P J Burke; P S Lietman Journal: Ann Intern Med Date: 1983-12 Impact factor: 25.391
Authors: Sharon Elad; Vinisha Ranna; Anura Ariyawardana; Maria Elvira Pizzigatti Correa; Vanessa Tilly; Raj G Nair; Tanya Rouleau; Richard M Logan; Andres Pinto; Veronica Charette; Debbie P Saunders; Siri Beier Jensen Journal: Support Care Cancer Date: 2016-11-16 Impact factor: 3.603
Authors: Sharon Elad; Yehuda Zadik; Ian Hewson; Allan Hovan; M Elvira P Correa; Richard Logan; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-06-11 Impact factor: 3.603
Authors: Deborah P Saunders; Joel B Epstein; Sharon Elad; Justin Allemano; Paolo Bossi; Marianne D van de Wetering; Nikhil G Rao; Carin Potting; Karis K Cheng; Annette Freidank; Michael T Brennan; Joanne Bowen; Kristopher Dennis; Rajesh V Lalla Journal: Support Care Cancer Date: 2013-07-06 Impact factor: 3.603
Authors: Ourania Nicolatou-Galitis; Pavlina Athanassiadou; Vassilis Kouloulias; Anastasia Sotiropoulou-Lontou; Konstantinos Dardoufas; Argy Polychronopoulou; Maria Gonidi; Konstantinos Kyprianou; Georgia Kolitsi; Christos Skarleas; George Pissakas; Ioannis S Papanikolaou; John Kouvaris Journal: Support Care Cancer Date: 2006-01-10 Impact factor: 3.359
Authors: Farah Wasim Aribi Al-Zoobaee; Loo Yee Shen; Sajesh K Veettil; Divya Gopinath; Mari Kannan Maharajan; Rohit Kunnath Menon Journal: Int J Environ Res Public Health Date: 2020-11-30 Impact factor: 3.390
Authors: Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal Journal: Ann Hematol Date: 2022-01-07 Impact factor: 3.673